Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients

详细信息    查看全文

• 作者：Luigi Coltelli^a ; ^{luigi.coltelli@gmail.com} ; Andrea Fontana^b ; ^{andrea.fontana@aruba.it} ; Sara Lucchesi^a ; ^{lucchesisara@libero.it} ; Laura Ginocchi^a ; ^{lauraginocchi@hotmail.it} ; Guido Bocci^c ; ^{guido.bocci@med.unipi.it} ; Mario Filidei^a ; ^{m.filidei@uslnordovest.toscana.it} ; Marco Scalese^d ; ^{scalese@ifc.cnr.it} ; Giada Arrighi^a ; ^{giada.arrighi@uslnordovest.toscana.it} ; Chiara Finale^a ; ^{chiarafinale@libero.it} ; Lorenzo Marcucci^a ; ^{lorenzo.marcucci@uslnordovest.toscana.it} ; Orlando Goletti^e ; ^{o.goletti@med.unipi.it} ; Barbara Salvadori^b ; ^{b.salvadori@ao-pisa.toscana.it} ; Ilaria Ferrarini^b ; ^{ilaria.ferrarini84@gmail.com} ; Eleonora Bona^f ; ^{bonaeleonora@tiscali.it} ; Alfredo Falcone^b ; ^g ; ^{alfredo.falcone@med.unipi.it} ; Giacomo Allegrini^a ; ^{g.allegrini@uslnordovest.toscana.it}
• 关键词：Breast ; Cancer ; Adjuvant chemotherapy ; Elderly ; Non-pegylated ; Liposomal ; Doxorubicin ; Cyclophosphamide ; Paclitaxel
• 刊名：The Breast
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：31
• 期：Complete
• 页码：186-191
• 全文大小：323 K
• 卷排序：31

文摘

Adjuvant NPL-DOX in elderly patients resulted in a low rate of cardiac side effects. No early episodes of symptomatic CHF within the first 12 months from the enrolment. Adjuvant NPL-DOX should be a therapeutic option in elderly breast cancer patients. Adjuvant NPL-DOX should be a therapeutic option in patients with CHF risk factor.